



Guillermo Torre Amione,
M.D. PhD

Biography

Rector of TecSalud and Vice President of Research at Tecnológico de Monterrey

Guillermo Torre, MD, PhD is one of the founders of the Transplant Laboratory at Houston Methodist Hospital and was a board member of the DeBakey Heart Center run by Houston Methodist Hospital and the University of St. Thomas.

He holds a degree in Surgery and Medicine from Tecnológico de Monterrey, with a specialty in Internal Medicine and a subspecialty in Interventional Cardiology, Heart Failure, and Transplantation from Baylor College of Medicine, and a Doctorate in Immunology from the University of Chicago.

Guillermo is a Level 3 member of the Conacyt National Research System, and has published more than 190 scientific articles with more than 12,000 citations, winning the SCOPUS award for the country's most cited author (2012). He has published five books and three patents (2 international and 1 national).

He is a member of the National Academy of Medicine, the American College of Cardiology, and the American Heart Association; he is certified as a specialist in Clinical Cardiology by the Mexican Council of Cardiology and certified in Internal Medicine, Cardiology, Heart Failure, and Transplantation by the American Board of Internal Medicine.

He is founder of the technology-based health company Nano4Heart and a board member of Cardiol Therapeutics and Sulfagenics, a company dedicated to the development of drugs for the treatment of heart failure.

During the COVID-19 pandemic, Guillermo has been an active participant in the development of strategies along with private and public sector leaders, including the Foreign Secretary. In TecSalud, he has led research protocols for the diagnosis and treatment of COVID-19, such as Phase 3 clinical trials of the mRNA COVID-19 vaccine manufactured by the CureVac laboratory. Since 2011, he has served as Rector of TecSalud at Tecnológico de Monterrey.

And now also as Vice President of Research at Tecnológico de Monterrey.